白细胞介素10
医学
胃肠病学
内科学
白细胞介素10受体,α亚单位
炎症性肠病
免疫学
移植
疾病
生物
Gα亚单位
基因
细胞因子
遗传学
蛋白质亚单位
作者
Zhiheng Huang,Kaiyue Peng,Xiaoqin Li,Ruiqin Zhao,Jie‐Yu You,Xiuyong Cheng,Zhaoxia Wang,Ying Wang,Bingbing Wu,Huijun Wang,Huasong Zeng,Zhuowen Yu,Cuifang Zheng,Yuesheng Wang,Ying Huang
标识
DOI:10.1097/mib.0000000000001058
摘要
BACKGROUND: Interleukin-10 (IL10) signaling plays an important role in the pathogenesis of very early onset inflammatory bowel disease (VEO-IBD) in children. However, little is known about the role of the IL10 axis in children with VEO-IBD in China. METHODS: The Chinese VEO-IBD Collaboration Group was created to collect clinical and genetic data from patients deficient in IL10 and the IL10 receptor. High-throughput sequencing was performed to identify mutations in these genes. RESULTS: We identified 32 compound heterozygous mutations and 9 homozygous mutations in IL10 receptor subunit alpha and 1 homozygous mutation in IL10 receptor subunit beta. Among these mutations, 10 novel mutations were identified, and 6 pathogenic mutations had been previously described. In patients with IL10 receptor subunit alpha mutations, c.301C>T (p.R101RW) and c.537 G>A (p.T179T) were the most common mutations. For 88.1% of the patients, the initial symptom was diarrhea, with a time of onset of 10.4 ± 8.0 days. Oral ulcers were the first symptom in 23.8% of the patients, with a time of onset of 9.7 ± 2.8 days. Extraintestinal manifestations included perianal abscesses (22/42), perianal fistulas (23/42), oral ulcers (20/42), and recurrent eczema (15/42). Twelve patients underwent enterostomy. These patients also had lower average Z scores in height-for-age and weight-for-age. Various treatment strategies were used, including fecal microbiota transplantation; however, only hematopoietic stem cell transplantation was efficacious. CONCLUSIONS: This study identified genotypes and phenotypes of Chinese VEO-IBD infants with IL10 receptor mutations. Our study expands the current knowledge on the involvement of the IL10 axis in patients with VEO-IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI